Janssen/J&J one-dose vaccine
Per the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA), extremely rare clotting events have been reported after vaccination with the Janssen (J&J) vaccine, primarily among women aged 18-49 years. Individuals should be aware of the availability of other FDA-authorized COVID-19 vaccines (i.e., mRNA vaccines). Review the Janssen/J&J patient fact sheet PDF for more information.